Clinical trial
Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With…
NCT00394173 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00394173 |
|---|---|
| Title | Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) |
| Official title | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of DNK333 25mg b.i.d. Given Orally for 4 Weeks in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Irritable Bowel Syndrome With Diarrhea (IBS-D) |
| Intervention type | Drug |
| Interventions | DNK333, Placebo |
| Enrollment | 180 |
| Start date | Sep 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Oct 31, 2006 |
| Last update posted | Feb 27, 2017 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: